ライフサイエンスコーパス: tail vein

1 203S-CypD or WT CypD into CypD(-/-) mice via tail vein.

2 ressure injection of a DNA solution into the tail vein.

3 3.7- to 7.4-MBq (18)F-FDG injection via the tail vein.

4 .0 MBq of (188)Re-(Arg(11))CCMSH through the tail vein.

5 x 14.8 MBq of (188)Re-(Arg(11))CCMSH via the tail vein.

6 construct was injected intravenously via the tail vein.

7 mice after injection of tumor cells into the tail vein.

8 l Research Institute mice inoculated via the tail vein.

9 -7.4 MBq [50-200 muCi]) was injected via the tail vein.

10 ns of fluorescent probe administered via the tail vein.

11 r (5-10 microg of protein) were injected via tail vein.

12 orescent protein (GFP)-positive BMCs via the tail vein.

13 ral blood CD34+ cells were injected into the tail vein.

14 In some rats, drugs were delivered via the tail vein.

15 nfected with Staphylococcus aureus through a tail vein.

16 llowing inoculation of myeloma cells via the tail vein.

17 bicin in the hepatic artery, portal vein, or tail vein.

18 rption maximum 636 nm) was injected into the tail vein.

19 lowing injection of carcinoma cells into the tail vein.

20 HER2)-Luc human breast cancer cells into the tail vein.

21 injected them into FIX knockout mice via the tail vein.

22 ion, mice received 100,000 MSC or saline via tail vein.

23 tganglionic neurones innervating the lateral tail veins.

24 ceived i.v. donor C3H cell infusions via the tail vein: 1) 5.0x10(7) wild-type donor spleen cells (SP

25 icle was administered systematically via the tail vein 30 min prior, and 30 min and 24 h after the oc

26 chamber of SCID mice was observed following tail vein administration (i.v.) of the PLL dendrimers.

27 ce with plasma FVII < 1% of normal, a single tail vein administration of AAV (1 x 10(13) vector genom

28 ice were visualized at 4, 12, and 24 h after tail vein administration of the (99m)Tc-CCND1 antisense

29 principal organ of tracer localization after tail-vein administration of 64Cu-PTSM alone.

30 ved from long-term, low-pressure, low-volume tail-vein administrations.

31 hat systemic transplantation of SHED via the tail vein ameliorates ovariectomy (OVX)-induced osteopen

32 ndibular gland (SMG) or to the liver via the tail vein and assessed transgenic protein expression and

33 s infused at a constant rate via the lateral tail vein and clonus onset was recorded in the presence

34 S100A9 concentrations in blood are lowest in tail vein and highest in the lungs, which most likely gu

35 ld-type controls, BrdU was injected into the tail vein and labeled on en face preparation.

36 bes BMV109 and BMV101, respectively, via the tail vein and noninvasively imaged by optical and small-

37 G while higher levels were obtained from the tail vein and the SMG; however, vector particle containm

38 kBq [20 micro Ci]) was administered via the tail vein and uptake was determined in selected tissues

39 ransduced SP cells were transplanted via the tail vein and were shown to successfully deliver enhance

40 venous (1 x 10(7). per mouse via the lateral tail vein), and muscle (1 x 10(8) CFU per mouse intramus

41 Photofrin (PF), 10 mg/kg, was injected by tail vein, and 24 h later, 630 nm light was delivered to

42 Tracer was injected via the tail vein, and dynamic PET scans were acquired for 90 mi

43 dextran-fluorescein isothyocyanate into the tail vein, and half of them were exposed to high-intensi

44 ICG was injected into the mouse tail vein, and images were taken by in vivo confocal mic

45 were injected into tumor-bearing mice via a tail vein, and these lipoplexes accumulated sufficiently

46 0(6) BMSCs in PBS (n=8) were injected into a tail vein at 1 day postischemia.

47 Rats were divided into three groups: tail vein bacterial injection on day 0 (no fibrin group)

48 GPI 562 caused a dose-dependent increase in tail vein bleeding time, but intracerebral hemorrhage (I

49 Anti-ADAMTS-18 Ab shortens the tail vein bleeding time.

50 Moreover, despite normal tail vein bleeding times, mKng1(-/-) mice displayed a si

51 similar activated partial thromboplastin and tail vein bleeding times.

52 gh injection of anti-TFPI antibody mitigated tail vein bleeding.

53 endently prolonged diluted thrombin time and tail-vein bleeding time, which were reversed by idaruciz

54 In tail vein blood collected on three separate days 60 min

55 Graft function was measured by daily tail vein blood glucose levels, with rejection defined a

56 ncer cells were injected either i.v. via the tail vein (circulating cell colonization assay) or direc

57 Furthermore, tail vein delivery of purified CCN1 protein accelerates

58 yielded up to 84-fold more hFIX protein than tail vein delivery, corroborated by similarly increased

59 expression in the liver of mice following a tail vein dose of a polyplex, composed of 1 mug of pGL3

60 ed contrast material was infused through the tail vein for 5 minutes.

61 ivered to the liver by a single hydrodynamic tail vein (HTV) injection.

62 in which diffuse MM lesions developed after tail vein i.v. injection of human RPMI-8226/S MM cells s

63 cells (1.2 x 106) were administered through tail vein immediately after reperfusion and at 6 hrs and

64 luciferase (5TGM1/luc) were inoculated from tail vein in bg/xid/nd mice.

65 acute liver injury, we transplanted them via tail vein in mice injected intraperitoneally with a sing

66 Adenovirus-PPARgamma1 injected into the tail vein induced hepatic steatosis in PPARalpha(-/-) mi

67 ing the production of [3-(13)C]lactate after tail vein infusion of labeled [1-(13)C]glucose.

68 Tail vein infusion of syngeneic MSC and MSC:SDF-1 1 day

69 ant pentylenetetrazol (PTZ), given via timed tail vein infusion.

70 oute of uptake with time-course MRI during a tail-vein infusion of manganese.

71 Animals received 6-hr tail vein infusions, commencing 18 hrs after cecal ligat

72 = 8) or replaced by HSV1-sr39tk (n = 18) was tail-vein injected into mice.

73 ell as in the liver and lungs of living mice tail-vein injected with coelenterazine.

74 , severe combined immunodeficiency mice were tail-vein injected with human melanoma cell lines (A375-

75 At 12weeks of age, brain uptake of tail vein-injected ((3))H-2-deoxy glucose in Glut3(+/-)

76 active and fails to trigger dissemination of tail vein-injected cells in a mouse model of metastasis.

77 etastasis of orthotopically implanted 4T1 or tail vein-injected MDA-MB-231T cells (P = 0.001 and 0.04

78 abetic and age-matched nondiabetic mice were tail vein-injected with 10(8) CFU of Klebsiella pneumoni

79 MicroPET images of living mice indicate that tail-vein-injected labeled C6 cells traffic to the lungs

80 yte number in living mice was assessed after tail vein injection (150 mug of each conjugate per mouse

81 4 (Pc 4), was delivered to each animal by a tail vein injection 48 h before laser illumination.

82 he number of metastatic nodules in mice with tail vein injection and orthotopic implantation.

83 In the subcutaneous xenograft and tail vein injection assays, these cells had significantl

84 tumor cell extravasation into the lung after tail vein injection compared with tumors expressing wild

85 substantially inhibited lung colonization in tail vein injection experiments in immunodeficient mice.

86 ty of approximately 12 MBq (64)Cu-GPVI-Fc by tail vein injection followed by delayed (24 hours) posit

87 promoter fragments was confirmed in vivo by tail vein injection followed by luciferase reporter assa

88 by adeno-associated viral vector via single tail vein injection immediately following induction of M

89 ), ex vivo in murine aortas, and in vivo via tail vein injection in a 24-h murine model.

90 ting capsids by direct in vivo panning after tail vein injection in mice.

91 n immunoliposomes to the mesangium following tail vein injection in mice.

92 the blood-brain barrier, to access brain via tail vein injection in mice.

93 merulus and glomerular mesangial cells after tail vein injection in normal and nephritic mice.

94 el and that DN-PPARgamma ECV304 cells, after tail vein injection in nude mice, form lumen-obliteratin

95 imental lung metastasis model established by tail vein injection in severe combined immunodeficient m

96 and metastasis in vitro and in cells before tail vein injection in vivo.

97 ous CIK cells were injected intravenously by tail vein injection into groups of mice, and the animals

98 )-labeled Abeta42 and Abeta40 introduced via tail vein injection into mice with a BBB rendered permea

99 Following tail vein injection into rats, (M6P)(20)-BSA-(33)P-TFO r

100 ferase-positive splenocytes, transferred via tail vein injection into the brains of HSV-infected anim

101 enhancer, was delivered through hydrodynamic tail vein injection into VWF knockout mice (VWF(-/-)) th

102 mic administration of siMGMT-SNAs via single tail vein injection is capable of robust intratumoral MG

103 in vivo BALB/c nude mice xenograft model and tail vein injection model showed that berberine treatmen

104 ased replication assay with the hydrodynamic tail vein injection model to investigate the function(s)

105 with ketamine/xylazine and catheterized for tail vein injection of (11)C-raclopride.

106 RLT was performed by administering a single tail vein injection of (177)Lu-PSMA-617 at different for

107 omized into subgroups that received either a tail vein injection of 3 x 10 orbital fat-derived stem/s

108 ution studies were done in male CD-1 mice by tail vein injection of 3.7 MBq (100 microCi) of the (11)

109 One and 2 h after tail vein injection of 30 x 10(6) ex vivo (18)F-FDG-labe

110 by counting tumor cells in lung at 6 h after tail vein injection of a mixture of fluorescently tagged

111 When SIRT4 was knocked down in vivo by tail vein injection of a shRNA adenovirus, we observed a

112 Tail vein injection of a standard Ad5-based vector into

113 rmed in an animal model of lung cancer using tail vein injection of A549 cells in SCID mice.

114 In adult mice, tail vein injection of AAV9-GFP leads to robust transduc

115 Tail vein injection of adenovirus expressing the HNF6 co

116 Finally, tail vein injection of an M2pep fusion peptide with a pr

117 A tail vein injection of anti-DLK1 Ab at 6 h after PH redu

118 PET data were acquired after tail vein injection of approximately 9 MBq of (18)F-FPAC

119 atic lung melanoma tumour-bearing mice after tail vein injection of both treatments, suggesting that

120 arrying s.c. LNCaP xenografts, a single i.v. tail vein injection of CV787 eliminates 300-mm3 tumors w

121 Tail vein injection of human endothelial specific Ulex e

122 lity of ultrafast multislice (13)C MRI after tail vein injection of hyperpolarized (13)C-phospholacta

123 Furthermore, tail vein injection of miR-223 lentiviral vector to miR-

124 to 4, microPET images were obtained after a tail vein injection of nitrogen-13 ammonia ([13N]-NH3) a

125 Following tail vein injection of OS cells into mice, both molecule

126 s of ocular and brain tissues after a single tail vein injection of SVV-001 (1 x 10(13) vp/kg) showed

127 A single tail vein injection of the rAAV8 vector was as efficient

128 njected dose per gram (%ID/g) 72 hours after tail vein injection of the radiolabeled probe in subcuta

129 the number of lung metastases 14 days after tail vein injection of tumor cells, with alveolar wall i

130 bserved in a VEGF-dependent manner following tail vein injection of tumor cells.

131 of Cre-recombinase in ILK-floxed animals by tail vein injection resulted in acute hepatitis, with a

132 earing B16/F10 and A375M tumors at 1 h after tail vein injection revealed good B16/F10 tumor-to-backg

133 er a functional human ABCC6 via hydrodynamic tail vein injection to approximately 13% of mouse hepato

134 ntibody (Ab; DOTA-30F11) was administered by tail vein injection to athymic mice bearing disseminated

135 CC, or control Cas9 vector, via hydrodynamic tail vein injection to livers of 8-week-old female FVB/N

136 ICAM-1 blocking antibody was administered by tail vein injection to mice following thoracic irradiati

137 was administered to Sprague-Dawley rats via tail vein injection using the carrier polyethylenimine.

138 pecific gene transfer following hydrodynamic tail vein injection using the kidney-specific podocin an

139 Metastasis to the lung via tail vein injection was reduced in the 4T1-WNT5A express

140 es for (18)F-FPA and (14)C-acetate 1 h after tail vein injection were 7.08 +/- 0.80 and 0.36 +/- 0.08

141 BALB/c mice were infected by tail vein injection with 2 x 10(5) organisms of wild typ

142 he rAAV FIX genome in liver and spleen after tail vein injection with a higher proportion in liver af

143 nockout (CD18-ko) and wild-type (WT) mice by tail vein injection with Listeria.

144 Male BALB/c mice were infected via tail vein injection with wild-type C. albicans or with a

145 s of CN-105 (0.05 mg/kg) was administered by tail vein injection within 24 hours after ICH induction.

146 asis from orthotopic primaries and following tail vein injection without further VEGF treatment.

147 Following lateral tail vein injection, 3T3 cells transformed by constituti

148 he vector was administered into nude mice by tail vein injection, and exogenous creatine was administ

149 ice were infected with MUP1 adenoviruses via tail vein injection, and recombinant MUP1 was overexpres

150 Following tail vein injection, fluorescence arising from dye-conju

151 , or phosphate buffered saline (PBS) through tail vein injection.

152 from anesthesia when administered to mice by tail vein injection.

153 pic reinjection and of lung metastases after tail vein injection.

154 showed increased pulmonary tumor growth upon tail vein injection.

155 idiasis with C. albicans A72 administered by tail vein injection.

156 ng in vivo bioluminescence imaging following tail vein injection.

157 livers of outbred ICR mice via hydrodynamic tail vein injection.

158 tively transferred to recipient mice through tail vein injection.

159 in the lung after systemic administration by tail vein injection.

160 . actinomycetemcomitans were transferred via tail vein injection.

161 HBV vector were codelivered via high-volume tail vein injection.

162 essed formation of lung metastases following tail vein injection.

163 ses of more aggressive carcinoma cells after tail vein injection.

164 to the livers of mice by using high-pressure tail vein injection.

165 pes simplex virus type 1-specific T cells by tail vein injection.

166 , such a high expression was not found after tail vein injection.

167 ion of the liver or by systemic delivery via tail vein injection.

168 with resting Aspergillus conidia via lateral tail vein injection.

169 HepG2 colonization into lung and liver after tail vein injection.

170 and administered to healthy mice by lateral tail vein injection.

171 by administering an insulin stimulation via tail vein injection.

172 ng proved fast clearance of the tracer after tail vein injection.

173 ration of 42.1 +/- 3.9 MBq of (18)F-FMISO by tail vein injection.

174 accumulation of M2pep in TAMs in vivo after tail vein injection.

175 re retained in the murine lung 6 h following tail vein injection; coexpression of EDG2 enhanced reten

176 ation and inhibits metastasis to lung in the tail-vein injection and the oral cavity xenograft models

177 nomas were treated with 10 mg/kg of 5-Se via tail-vein injection and with 720 J cm(-2) of 570-750-nm

178 In mouse tail-vein injection experiments, a construct containing

179 pharmacokinetic data equivalent to data from tail-vein injection for small-animal (18)F-FDG PET.

180 nvasion and formation of lung colonies after tail-vein injection in SCID mice.

181 mine or polyethyleneimine alone (placebo) by tail-vein injection into nude mice with prostate and bre

182 In a tail-vein injection metastatic model, Frzb-transfected H

183 ost-myocardial infarction were randomized to tail-vein injection of 2x10(6) MSCs, with injection repe

184 MIR122 was inhibited in mice by tail-vein injection of an oligonucleotide antagonist of

185 Tail-vein injection of B16-F10 cells that stably express

186 tal metastasis assay we detail here includes tail-vein injection of cancer cells into the mouse and d

187 Orthotopic reinjection and tail-vein injection of cells arising from tumors, couple

188 ing, CCl4 is administered for 12 weeks after tail-vein injection of Cre-expressing adenovirus (adeno-

189 Hydrodynamic tail-vein injection of MAN2A1-FER resulted in rapid deve

190 Other groups received a tail-vein injection of serum from either HDM-sensitized

191 cell lines and for metastasis as assessed by tail-vein injection of three different tumorigenic cell

192 tinal (GI) tumors in immunodeficient mice by tail-vein injection rather than surgery.

193 ransposon, delivered as naked plasmid DNA by tail-vein injection, to integrate B-domain-deleted FVIII

194 of these cells to form lung metastases after tail-vein injection, whereas mTerc reconstitution alone

195 cally investigated using intraperitoneal and tail-vein injection.

196 d 1 hr after initiation of sepsis via single tail-vein injection.

197 ility form lung metastases in mice following tail-vein injection.

198 le to form pulmonary tumor nodules following tail-vein injection.

199 BL/6J mice were randomly assigned to receive tail vein injections of 1 mug/kg of remifentanil or norm

200 or TBI dose level per experiment were given tail vein injections of 100 microg of (131)I-labeled 30F

201 In this study, we show that mouse tail vein injections of adenovirus expressing the rat HN

202 In tail vein injections of alternative cancer models, bicar

203 Tail vein injections of Sod2-GFP-expressing HT-1080 cell

204 ter implantation only (n = 99); 176 received tail vein injections of Staphylococcus epidermidis on po

205 toris (phLAL), purified, and administered by tail vein injections to lal( -/-) mice.

206 ioned with carbon monoxide were delivered by tail vein injections to septic mice.

207 evels during BDL liver injury, we used mouse tail vein injections with recombinant adenovirus express

208 and lung colonization after subcutaneous and tail vein injections, respectively.

209 hydrolase (Fah) mutant mice via hydrodynamic tail vein injections.

210 e-matched, irradiated LH(BETA)T(AG) mice via tail vein injections.

211 NS alphaS pathology in M83 mice than i.p. or tail vein injections.

212 aluated AAV8 against AAV2 in intraportal and tail vein injections.

213 ificantly larger effects in both organs than tail vein injections.

214 ey rats (n = 36) were studied at 9.4 T after tail vein injections.

215 lung cancer cell dissemination in mice after tail vein injections.

216 In addition, tail-vein injections in mice with human breast cancer MC

217 ice with hepatic deletion of PTEN were given tail-vein injections of MAN2A1-FER.

218 butions of the nanoparticles 24 h after i.v. tail-vein injections show that the nanoparticle accumula

219 xpressed in the mouse liver via hydrodynamic tail-vein injections.

220 detected in both spleen and brain 3 wk after tail vein inoculation, and it induced expression of infe

221 After tail vein inoculation, most luciferase-generated biolumi

222 ng Transwells, and lung metastasis following tail vein inoculation.

223 d cause a lethal infection in mice following tail vein inoculation.

224 istration of human lysosomal acid lipase via tail vein into mice with atherosclerosis eliminates earl

225 uorobenzoate (2-3 MBq) were injected via the tail vein into nude mice xenografted with BxPC3 (integri

226 nsduced B16 melanoma cells were injected via tail vein into syngeneic C57BL/6 mice.

227 chieved by the parent compounds, yet free of tail vein irritation and histamine induced toxicity in v

228 munocompromised mice, and when injected into tail veins, led to lung metastasis.

229 particles injected intravenously through the tail vein lodged preferentially in the lung, distributin

230 n vitro and metastatic foci development in a tail vein lung metastasis model in mice.

231 compared with wild-type controls, both in a tail vein metastasis assay using isogenic melanoma cells

232 nd, heterotopic murine Lewis lung cancer and tail vein metastasis tumor model systems in betaarr2-def

233 drochloride liposomes were injected into the tail vein: Mice received therapy with doxorubicin inject

234 prime determinant of virulence in the mouse tail vein model of candidiasis and that the attenuated v

235 inant metastatic disease in the lung using a tail vein model of haematogenous spread through accelera

236 idence of lung metastasis in vivo in a mouse tail vein model.

237 F), and this conjugate was injected into the tail vein of aged Fischer 344 male rats (24 months) twic

238 ffinity chromatography and injected into the tail vein of apolipoprotein E-deficient mice.

239 ic this pathology, Tat was injected into the tail vein of C57BL/6 mice.

240 so shown that human apo(a) injected into the tail vein of control mice undergoes degradation as refle

241 llow tracking in vivo, and injected into the tail vein of female mice at different ages.

242 assay in which cells were injected into the tail vein of immunodeficient mice.

243 g shRNA against chk was injected i.v. in the tail vein of MDA-MB-231 tumor-bearing female severe comb

244 ted into the circulation through the lateral tail vein of mice, IGF1R disruption also resulted in sig

245 injection of the complexes into the lateral tail vein of mice.

246 t by i.v. administration of a mAb(s) via the tail vein of mice.

247 go in culture and injected into the flank or tail vein of SCID mice, eventual tumor volume and number

248 MBq (104 ng) of radiolabeled antibody in the tail vein of SCID mice, which were then sacrificed at 1,

249 enovirus vector, which was injected into the tail vein of severe combined immunodeficient mice.

250 in the mammary fat pad or injected into the tail vein of syngeneic rats, and effects of doxycycline-

251 rt here that B16F10 cells, injected into the tail vein of UG-KO mice, form markedly elevated numbers

252 Furthermore, after injection into the tail veins of BALB/c mice, CSF-1R-expressing clones also

253 n these transfected cells were injected into tail veins of C57BL/6 mice, B16-FTIII.M cells expressing

254 9H11] in the bilayer, were injected into the tail veins of female BALB/c mice bearing right flank EMT

255 Following intravenous injection in the tail veins of homozygous M83 transgenic (M83(+/+)) mice,

256 ental cells or 435.eB transfectants into the tail veins of ICR-SCID mice demonstrated that mice injec

257 bitor RNAs against PPP1R1, injected into the tail veins of immune-compromised mice, and followed by n

258 actions were administered intravenously into tail veins of mated BALB/c females at day 0 of pregnancy

259 MV-Edm administered intravenously into the tail veins of mice also showed significant antineoplasti

260 s was injected into the mammary fat pads and tail veins of mice to evaluate tumor growth, and experim

261 Following injection into the tail veins of mice, longer chain complexes gave signific

262 truct was injected hydrodynamically into the tail veins of mice.

263 Klebsiella pneumoniae was injected into the tail veins of rats and followed with multiple doses of p

264 ific T clone cells were transferred into the tail veins of rats.

265 of 1 x 10(7) T-bodies were injected via the tail vein or directly administered to the subcutaneous t

266 d or 4-fold higher level of hFIX compared to tail vein or intramuscular injections, respectively.

267 MSO]/physiologic saline) by intravenous (iv) tail vein or intraperitoneal (IP) injection immediately

268 mouse melanoma cells were injected into the tail vein or portal vein of 6-week-old C57BL/6 and nude

269 with SNORA42-siRNA into mice through either tail vein or subcutaneous injection.

270 as injected into mice via the portal vein or tail vein, or directly into the liver parenchyma, and th

271 r injection of vector particles into muscle, tail vein, or portal vein were similar with hFIX detecta

272 14), or 1.0 mg/kg (n = 14) twice weekly via tail vein, or to control groups (n = 13) receiving the v

273 omoter (pCMV-HGF) by rapid injection via the tail vein produced a remarkable level of human HGF prote

274 were injected into the mammary fat pads and tail veins, respectively, of athymic nude mice and asses

275 (WT) littermate control C57BL/6 mice via the tail vein, s.c., and intrasplenic routes.

276 he rats were infused with the test agent via tail vein shortly before being tested for seizure suscep

277 inistered by injection into NOD mice via the tail vein, this FSI formulation significantly suppressed

278 viral genome particles/vector/mouse) via the tail vein to 1-month-old dystrophin-null mice.

279 urine spleen to generate liver metastases or tail vein to generate lung metastases with sequential pr

280 ion probes, as well as sequence controls, by tail vein to immunocompromised female NCr mice bearing h

281 cted with streptozotocin (65 mg/kg) into the tail vein to induce diabetes (defined by blood glucose l

282 les were injected into pregnant mice through tail veins to mimic bacteremia, which occurs frequently

283 lactic efficacy in protecting HemA mice from tail vein transection bleeding induced 24-48 hours after

284 30% higher survival relative to rFVIII after tail vein transection inflicted 24 hours after dosing.

285 emic injections of 30 mg/kg MnCl2 H2O in the tail vein using T1-weighted magnetic resonance imaging (

286 V RNA sequences were injected into the mouse tail vein using the hydrodynamics-based transfection pro

287 anial melanoma xenografts in SCID mice after tail vein virus application.

288 Eight mice were fasted, the tail vein was injected with 150-300 microCi of FDG and d

289 After injecting mice with rPfHRP2 via the tail vein, we compared analyte levels in both plasma and

290 nous model, bacteria inoculated in the mouse tail vein were observed spreading to multiple tissues.

291 ollected 2 h after mice were injected in the tail vein with (64)Cu-CB-TE2A-LLP2A (5.6-11.1 MBq [150-3

292 Mice were injected via the tail vein with 1.9-3.1 MBq (53-85 microCi) of (124)I-min

293 aring MCF-7 xenografts were injected via the tail vein with 10.5 MBq (283 microCi, 0.235 microg/kg) o

294 er, groups of 3-5 mice were injected via the tail vein with 50 microg of either scVEGF that had been

295 dertaken by injecting male CD-1 mice via the tail vein with 6.03 MBq (163 microCi, 2.55 microg/kg) of

296 nal groups of 3-5 mice were injected via the tail vein with 74-111 MBq of (99m)Tc-scVEGF (or (99m)Tc-

297 termined by injecting male CD-1 mice via the tail vein with either (11)C-BMS-5p 3 or (18)F-FBzBMS 5.

298 or in vivo studies, 15 mice were injected by tail vein with increasing levels of an adenoviral vector

299 Mice were injected into the tail vein with liposome-encapsulated hemoglobin or lipos

300 control proteins and challenged them via the tail vein with S. aureus or other gram-positive or gram-